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Abstract
Background: A prime-boost vaccination regimen with ALVAC-HIV (vCP1521) administered intramuscularly at 0, 4, 12, and 24
weeks and gp120 AIDSVAX B/E at 12 and 24 weeks demonstrated modest efficacy of 31.2% for prevention of HIV acquisition
in HIV-uninfected adults participating in a community-based efficacy trial in Thailand.
Methodology/Principal Findings: Reactogenicity was recorded for 3 days following vaccination. Adverse events were
monitored every 6 months for 3.5 years, during which pregnancy outcomes were recorded. Of the 16,402 volunteers, 69% of
the participants reported an adverse event any time after the first dose. Only 32.9% experienced an AE within 30 days
following any vaccination. Overall adverse event rates and attribution of relatedness did not differ between groups. The
frequency of serious adverse events was similar in vaccine (14.3%) and placebo (14.9%) recipients (p=0.33). None of the 160
deaths (85 in vaccine and 75 in placebo recipients, p=0.43) was assessed as related to vaccine. The most common cause of
death was trauma or traffic accident. Approximately 30% of female participants reported a pregnancy during the study.
Abnormal pregnancy outcomes were experienced in 17.1% of vaccine and 14.6% (p=0.13) of placebo recipients. When the
conception occurred within 3 months (estimated) of a vaccination, the majority of these abnormal outcomes were
spontaneous or elective abortions among 22.2% and 15.3% of vaccine and placebo pregnant recipients, respectively
(p=0.08). Local reactions occurred in 88.0% of vaccine and 61.0% of placebo recipients (p,0.001) and were more frequent
after ALVAC-HIV than AIDSVAX B/E vaccination. Systemic reactions were more frequent in vaccine than placebo recipients
(77.2% vs. 59.8%, p,0.001). Local and systemic reactions were mostly mild to moderate, resolving within 3 days.
Conclusions/Significance: The ALVAC-HIV and AIDSVAX B/E vaccine regimen was found to be safe, well tolerated and
suitable for potential large-scale use in Thailand.
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HIV/AIDS has emerged as a worldwide public health threat
and is associated with high morbidity and mortality. Worldwide,
the total number of people living with HIV in 2009 was estimated
to be 33.3 million with 2.6 million being newly infected [1]. In
Thailand, 14,000 new HIV infections occur each year despite the
considerable efforts and success in controlling the HIV epidemic
[2,3]. The circulating recombinant form CRF01_AE and subtype
B dominate the HIV epidemic in Thailand [4,5]. The develop-
ment of a safe, effective, easily administered and inexpensive AIDS
vaccine is desperately needed worldwide, and the Thai Ministry of
Public Health has long recognized that need and has strongly
supported HIV vaccine research in Thailand [6,7]. An AIDS
vaccine as part of a comprehensive prevention package is
considered the best long-term solution in controlling the HIV/
AIDS pandemic [8,9]. Safety is a paramount consideration for all
preventive vaccines. Monitoring and assessing vaccine safety is a
priority for public health. It is generally thought that such
interventions must have modest rates of reactions and only rare
severe or serious events associated with their use [10,11].
This prime-boost concept applied to AIDS vaccines employs
viral vector prime together with a soluble envelope subunit boost.
The concept is aimed specifically at inducing both CD4+ and
CD8+ T-cell as well as binding and neutralizing antibody immune
responses [12–15]. An effective immune response will likely
comprise a combination of antibodies and CD4+ and CD8+ T
cells that recognize, neutralize and/or destroy diverse strains of
HIV before an infection becomes irreversibly established [16].
Given the hurdles of eliciting broadly neutralizing antibodies, the
focus of HIV vaccine development in recent years turned to
evaluating vaccines capable of reducing viral replication after
infection (‘‘T-cell vaccines’’) [17,18]. Although contradicted by
some studies [19], control of viral replication could conceivably
slow the rate of disease progression as suggested by non-human
primate (NHP) challenge studies [20–23] and/or reduce trans-
mission of HIV from infected vaccine recipient to partner [24].
Earlier HIV vaccine trials from 1994–2000 tested recombinant
protein candidate vaccines that were capable of inducing antibody
responses [25]. One of these, a bivalent recombinant gp120
(AIDSVAX B/E) derived from HIV-1 CRF01_AE and B subtypes
was tested in Phase I/II trials and was shown to be safe and
immunogenic [26,27]. A Phase III trial using AIDSVAX B/E in
Thai injecting drug users, while confirming safety, did not provide
evidence of protection against HIV acquisition. In addition, a
concurrent Phase III trial using a bivalent gp120 subtype B
vaccine (AIDSVAX B/B9), among North American and European
men who have sex with men and women at high risk for
heterosexual transmission of HIV, did not protect against HIV
infection [28,29].
Attenuated non-replicating poxvirus vectors, in particular
canarypox (ALVAC) vectors, have been extensively studied and
appeared to be safe in phase I and II clinical studies [30]. ALVAC
prime and recombinant gp160 or gp120 boosts induced cell-
mediated immune responses together with significantly enhanced
antibody responses in HIV-uninfected volunteers. These initial
clinical studies conducted on a limited number of healthy subjects
in various parts of the world have documented the safety profile of
these two vaccines alone or combined in prime-boost regimen
[31–42]. In Thailand, phase I/II trials of ALVAC-HIV (vCP1521)
and several recombinant gp120 or gp160 boosts showed that the
vaccines were well tolerated and immunogenic [27,43,44]. These
preliminary studies led to efficacy testing of this prime-boost
regimen in a large (.16,000 persons) trial initiated in 2003 in
Rayong and Chon Buri provinces of Thailand. The trial
demonstrated a modest efficacy of 31.2% for prevention of HIV
acquisition compared to placebo in a modified intention-to-treat
analysis [45]. This prime-boost regimen had demonstrated an
adequate safety profile in previous human studies that allowed
advancement to full-scale efficacy testing. These large-scale,
randomized, controlled efficacy studies provide the most valid,
time-tested approach for evaluation of adverse events that may be
related to vaccination in the targeted population. This paper
presents the safety and tolerability profile of ALVAC-HIV and
AIDSVAX B/E in 16,402 volunteers participating in the RV144
Thai Phase III HIV vaccine study.
Methods
Study Setting
The study was conducted through facilities of the Thai Ministry
of Public Health in Rayong and Chon Buri provinces. The
protocol for this trial and supporting CONSORT checklist are
available as supporting information; see Checklist S1 and Protocol
S1. This trial is registered at clinicaltrials.gov, registry number
NCT00223080.
Participants
Eligible HIV-uninfected male and female adults aged 18–30
years from the general population in Rayong and Chon Buri
provinces of Thailand were enrolled and randomly assigned to
vaccine or placebo. Pregnant and breastfeeding women were
excluded from trial participation. Female participants were
advised to practice effective birth control and avoid pregnancy
until 3 months after the last vaccination [45].
Ethical Compliance
The protocol was reviewed by the ethics committees of the
Ministry of Public Health, the Royal Thai Army, Mahidol
University, and the Human Subjects Research Review Board of
the U.S. Army Medical Research and Materiel Command. It was
also independently reviewed and endorsed by the World Health
Organization and the Joint United Nations Program on HIV/
AIDS and by the AIDS Vaccine Research Working Group of the
National Institute of Allergy and Infectious Diseases at the
National Institutes of Health [45]. All participants provided their
written informed consent. An independent Data and Safety
Monitoring Board conducted periodic reviews for safety, futility,
and efficacy.
Interventions
RV144 was a community-based, multicenter, randomized,
double blind, placebo-controlled efficacy trial of the recombinant
canarypox vector vaccine ALVAC-HIV (vCP1521) and recombi-
nant gp120 AIDSVAX B/E administered in a prime-boost
vaccination regimen [45]. Eligible participants received ALVAC-
HIV (vCP1521) (Sanofi Pasteur, Swiftwater, PA, USA) or placebo
at weeks 0, 4, 12 and 24 and AIDSVAX B/E (Global Solutions for
Infectious Diseases, South San Francisco, CA, USA) or placebo at
weeks 12 and 24. ALVAC-HIV is a live recombinant canarypox
vector vaccine that has been genetically engineered to express
subtype E HIV-1 gp120 (strain 92TH023) linked to the
transmembrane anchoring portion of gp41 (strain LAI), and
HIV-1 gag and protease (LAI strain). ALVAC-HIV is grown in
chicken embryo fibroblasts and formulated at a dose of 10
6
CCID50 with 10 mM Tris HCl, pH 9 and lactoglutamate.
ALVAC-HIV is formulated as a lyophilized vaccine for injection
and is reconstituted with 1.0 mL of sterile sodium chloride (0.4%
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purified mixture of gp120 proteins produced by recombinant
DNA procedures using Chinese hamster ovary (CHO) cell
expression. The sequences of MN gp120/HIV-1 and A244
gp120/HIV-1 are expressed as fusion proteins where a 27 amino
acid sequence of the herpes simplex virus type 1 gD protein is
fused to the amino terminus of each protein. MN and A244
rgp120/HIV-1 are combined to produce the bivalent AIDSVAX
B/E vaccine. AIDSVAX B/E is supplied as a sterile suspension in
single-use glass vials. Each vial has a nominal content of 1 mL
(300 mg/mL) of each rgp120/HIV-1 protein adsorbed onto a total
of 600 mg aluminum hydroxide gel adjuvant. ALVAC placebo was
a sterile, lyophilized preparation consisting of a virus stabilizer in
1 mL of 0.4% sodium chloride while AIDSVAX placebo consisted
of 600 mg aluminum hydroxide gel adjuvant. ALVAC-HIV or
placebo was administered in the deltoid muscle of the left arm and
AIDSVAX B/E or placebo in the deltoid muscle of the right arm.
Female volunteers were vaccinated only if a urine pregnancy test
was negative the day of the vaccination visit.
Objectives
The primary objective of this analysis was to evaluate the safety
and reactogenicity of ALVAC-HIV and recombinant gp120
AIDSVAX B/E administered in a prime-boost vaccination
regimen. The results of vaccine efficacy and immunogenicity have
been published elsewhere [45].
Outcomes
Local reactions were separately recorded for each of the
ALVAC-HIV or placebo and AIDSVAX B/E or placebo
injections since they were administered in separate arms. Selected
adverse events monitored included local reactions at the injection
site - namely erythema, induration (mild: 1–9 mm; moderate: 10–
19 mm; severe: .20 mm), pain and tenderness, swelling and
limitation of arm movement and the systemic reactions of fever
(oral temperature $37.8uC), tiredness, myalgia, arthralgia,
headache, rash and nausea, vomiting and are hereafter termed
‘‘post vaccination reactions’’. Systemic reactions following the third
and fourth vaccinations could not be attributed to the ALVAC-
HIV or AIDSVAX B/E separately as both were administered at
the same time. Systemic events that had a clearly recognized cause
not related to the vaccination (for example dengue fever) were not
reported as ‘‘post-vaccination reactions’’.
Reactogenicity was self-reported for 3 days on diary cards,
which were reviewed by the nurse and the volunteer at the next
visit. If the nurse observed inconsistencies, the volunteer would
correct the card and the corrected information then recorded into
the case report form. If there were blanks on the card or the
volunteer could not remember, the volunteer was not allowed to
fill in the card from memory and was instructed to put a dash for
the value.
If unusual or severe signs or symptoms occurred after
vaccination, subjects were instructed by study personnel to seek
medical attention within the district where they were vaccinated or
at another Ministry of Public Health facility. Staff at health centers
referred volunteers to the district hospital for further evaluation
and treatment as appropriate. These subjects, if possible, were
followed up clinically until resolution of symptoms.
An adverse event (AE) was defined as any undesired, noxious or
pathological change in participants as indicated by physical signs,
symptoms, and/or laboratory changes that occurred following
administration of one of the vaccines, whether or not considered
vaccine-related. This definition included intercurrent illnesses or
injuries, and unexpected exacerbations of pre-existing conditions.
Anticipated day-to-day fluctuations of pre-existing conditions that
did not represent a clinically significant exacerbation were not
considered adverse events. Discrete episodes of chronic conditions
occurring during the study period were reported as adverse events
in order to assess changes in frequency or severity.
All adverse events occurring up to week 54 (20 weeks post last
vaccination) that resulted in an encounter with a health care
provider (physician, nurse, etc) were elicited, recorded on source
documents and transcribed onto case report forms (CRF). After
week 54, and up to week 184, only AE’s that were ‘‘medically
significant’’, defined as requiring multiple visits (two or more) to a
physician for the same condition, or that resulted in hospitalization
or an emergency room visit, were captured on source documents
and CRF. Medications were reported in association with all AE.
Data on serious adverse events (SAE as per definition of the U.S.
Food and Drug Administration) occurring through the whole
period of the study were collected and recorded on CRF, as well as
reported separately on SAE report forms. A subject with an SAE
was followed carefully until the condition resolved or stabilized
and/or chronicity was established. Any medication or other
therapeutic measure taken to relieve symptoms of the medical
problem was recorded on the CRF with the report of the outcome
on the SAE forms. Deaths were recorded and their causes
determined to the extent possible.
All AEs, including reactogenicity events, were graded as mild,
moderate and severe as recommended by the Division of Acquired
Immunodeficiency Syndrome of the National Institutes of Allergy
and Infectious Diseases, and categorized according to the Medical
Dictionary for Regulatory Activities (MedDRA) organ class
system. Relationship to vaccination was established by a study
physician at the time of reporting without knowledge of treatment
assignment
Pregnancy outcomes were recorded, including spontaneous and
induced abortions. Pregnancy outcome information was obtained
from hospital records when available or from the volunteer. The
time from estimated conception to the last vaccination prior to
pregnancy diagnosis was calculated.
Sample Size
Sample size for this efficacy trial was designed to detect a
vaccine-associated 25% decrease in the hazard rate during the
vaccination period and 50% in the subsequent 3 years. A placebo
arm infection rate of 0.34%/year was assumed using the lower
bound of the 95% confidence interval from a field study in Chon
Buri of 20–30 year olds. With up to 5% losses to follow-up per 6
month period, a total sample of 16,000 subjects provided 90%
power using a two-sided 5% Type 1 error rate, to detect vaccine
efficacy greater than zero. Event rate differences greater than 3%
can be detected with .90% power when the true rates are near
50%.
Randomization and Blinding
Randomization used centrally (EMMES Corporation) generat-
ed permuted blocks of random sizes for a set of coded treatment
labels that coincided with coded treatment stocks. Study
pharmacists, independent of other site staff and blinded to the
contents of the coded treatment stocks, maintained the random-
ization lists and prepared opaque syringes for clinic staff. Study site
staff, volunteers, and laboratories remained blinded with respect to
the allocation of placebo or vaccine.
Statistical Methods
Demographic and safety comparisons included all volunteers in
an intention-to-treat analysis. Reactogenicity, adverse events and
ALVAC-HIV and AIDSVAX B/E Safety in Thailand
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arm. Proportions experiencing reactions overall and after
individual vaccinations along with product-limit estimates of time
to adverse and serious adverse events were computed. Frequencies
of specific safety events and pregnancy outcomes were compared
across study arms using a chi-square test to evaluate the null
hypothesis that safety event rates are the same in both study arms
and the Wilcoxon test was used to compare severity grades. Odds
ratios were estimated with logistic regression and p values ,0.05
were considered significant.
Results
Participant flow
The CONSORT flow diagram of the trial has been published
elsewhere [45]. A total of 16,402 study volunteers were
randomized (8,202 and 8,200 vaccine and placebo recipients,
respectively), including 10,068 (61.4%) male participants. Of the
total, 14,802 completed the study. Seven volunteers (5 vaccine and
2 placebo recipients) were HIV-infected at baseline. Six random-
ized cases did not receive the initial vaccination and 13,973
(85.2%) received all four doses of vaccine or placebo. A total of
1,593 (9.7%) volunteers discontinued visits from the study: 796
(9.7%) from vaccine and 797 (9.7%) in placebo group. The reasons
included: loss to follow-up, refusal of further participation,
geographic relocation, death, and unknown reasons.
Recruitment
The study lasted from October 2003 to June 2009. The
demographic characteristics of the vaccine and placebo groups are
shown in Table 1.
Reactogenicity
Reaction reporting was typically complete and bounded by no
more than 5% loss for each time point requested. For example,
after the first vaccination, 4.2% of the volunteers were missing the
6-hour local reaction assessments, which decreased to 1.7% at the
72-hour assessment. A majority of participants experienced local
and systemic reactions, but more occurred in vaccine recipients
(7,442; 91.9%) as compared to placebo (6,141; 75.7%) recipients
(p,0.001). We examined reaction rates after the first dose in
participants who returned to receive subsequent doses compara-
tively to those who discontinued vaccinations. Overall reactoge-
nicity rates were higher in participants who discontinued
comparatively to those who returned (90.5% vs. 86.9% in vaccine
recipients, respectively, p=0.021; 64.5% vs. 56.0% in placebo
recipients, respectively, p,0.001).
Local reactogenicity. Considering all doses administered,
local reactions were more frequently observed in vaccine
(ALVAC-HIV and/or AIDSVAX B/E) (7,125; 88.0%) than in
placebo recipients (4,942; 61.0%) (p,0.001). Local reactions were
more common after the first dose (81.3% for vaccine recipients vs.
32.5% for placebo recipients, p,0.001), and reaction rates were
lower with subsequent doses (60.8% vs. 24% after second dose,
p,0.001).
ALVAC-HIV induced a higher frequency of reactions (87.8%)
than AIDSVAX B/E (54.6%) (p,0.001) (Table 2). For both
products, pain and/or tenderness were the most frequent local
reactions observed, followed by arm movement limitation. All
reactions were generally mild and transient, resolving within 3
days. The proportion of participants with individual local reaction
types, with the exception of induration and erythema (,4% for
ALVAC-HIV and ,1% for AIDSVAX B/E), was significantly
higher in the vaccine group than in the placebo group (p,0.001)
for all types of reactions (Table 2).
Systemic reactogenicity. Participants reported systemic
reactions more frequently in the combined vaccine group (6,252;
77.2%) than in the placebo group (4,850; 59.8%) (p,0.001). The
characteristics and frequency of systemic reactions reported are
shown in Table 3. Fatigue, myalgia, headache, and arthralgia were
the most common reactions reported in both study arms and were
significantly higher in vaccine than in placebo recipients
(p,0.001). Rash was reported infrequently (,5%) and at similar
rates by both vaccine and placebo recipients. Symptoms typically
resolved within 3 days.
Severity of reactions. As shown in Figure 1, local and
systemic reactions were mostly mild to moderate in severity.
However, moderate to severe reactions were significantly more
common (3,904; 48.2%) in vaccine than in placebo recipients
(2,101; 25.9%) (p,0.001) and in ALVAC-HIV (2,706; 33.4%)
than AIDSVAX B/E (634; 8.8%) recipients (p,0.001)(not shown).
Adverse Events
Overall, 69% (11,310) of the participants reported an AE any
time on study after the first dose administration, while only 32.9%
(5,394) experienced an AE within 30 days after any vaccination. A
total of 27,657 episodes of AEs was reported: 13,692 in vaccine
and 13,965 in placebo groups. The AE rate in the month post
vaccination declined from 15.9% after the first administration to
11.0% after the second and 8.6% after the last two vaccinations.
The proportion of subjects experiencing an AE after any
vaccination was not significantly different in vaccine and placebo
recipients (p=0.197) as shown in Table 4. Overall, the odds ratio
for an increased AE rate with vaccination was 0.97 (95% CI 0.90–
1.03). At 6, 12 and 42 months the estimated AE rates for the
combined treatment arms were 47.7%, 57% and 71.5%. The AE
rates were significantly different (p,0.001) for both age and sex in
both vaccine and placebo groups (Table 5).
Table 1. Demographic characteristics of RV144 participants in vaccine and placebo groups.
Vaccine (n=8,202) Placebo (n=8,200) Total (n=16,402)
n( % ) n( % ) n( % )
Sex Male 5,037 (61.4) 5,031 (61.4) 10,068 (61.4)
Female 3,165 (38.6) 3,169 (38.6) 6,334 (38.6)
Age Years #20 2,300 (28) 2,246 (27.4) 4,546 (27.7)
21–25 3,635 (44.3) 3,709 (45.2) 7,344 (44.8)
$26 2,267 (27.7) 2,245 (27.4) 4,512 (27.5)
doi:10.1371/journal.pone.0027837.t001
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infestation’ in 38.8%, followed by ‘injury, poisoning and
procedural related complications’ in 31.0% of the participants;
results were comparable in both vaccine and placebo groups.
Although many of the events (49%) in each group were mild in
severity, the combination of moderate (35%), severe (15%) and
potentially life-threatening (,1%) events accounted for nearly
50% of AEs in each group. A limited and similar number of deaths
(,1%) were reported in both groups during the study. The
majority of all events (95%) in both groups were assessed as not
related to vaccination and 97% required no change in the vaccine
schedule and resolved. Further characteristics of the events are
described in Table 6.
A total of 604 volunteers (3.7%; 307 vaccine and 294 placebo
recipients), experienced an AE or SAE which was possibly,
probably or definitely related to the product in any month after
vaccine administration (p=0.59). The rates of AEs and SAEs
attributed to vaccine did not statistically differ between vaccine
and placebo recipients.
AEs led to vaccination discontinuation in 66 individuals (0.4%)
overall; 34 (0.4%) vaccine and 32 (0.4%) placebo recipients.
Eleven of these discontinuations (6 vaccine and 5 placebo
recipients) were categorized as related to a product-related AE
including angioedema, urticaria, rash/eyelid swelling, headache,
syncope (vaso-vagal event) and nephrotic syndrome in the vaccine
group and lymphadenitis, lip/eyelid angioedema and rash (n=3)
in the placebo group.
Serious Adverse Events
A total of 2,912 SAEs (1,428 in vaccine and 1,484 in placebo
groups) were reported by 2,394 volunteers (14.6%) with no
evidence of a significant difference between vaccine (1,175;
14.3%) and placebo recipients (1,219; 14.9%) (p=0.33) with an
odds ratio for active vaccination of 0.96 (95% CI 0.88–1.04). At
6, 12 and 42 months the estimated SAE rates for the combined
treatment arms were 2.8%, 5.2% and 15.8% and a difference
between distributions for the times to SAEs were not different by
treatment arm. Most SAEs occurred outside the vaccination
months with ,2% SAE rate during the 30 days post treatment as
shown in Table 4. However, female gender was significantly
associated with higher SAE frequencies (15.5% in female vs.
13.6% in male vaccine recipients and 16.9% vs. 13.6% in placebo
recipients, p,0.001) (Table 5). Both type and frequency of SAEs
were similar between vaccine and placebo groups (Table 7). SAEs
coded under ‘Injury and procedural related complications’ were
the most common type reported followed by those in the
‘Infection and Infestation’ category. More than 90% of the SAEs
were graded moderate to potentially life threatening in both
groups (p=0.32). However, 99.9% were scored as not related to
the product administration in either group, and ,2% discontin-
ued or delayed vaccination. Six SAEs were scored as unlikely
related to vaccine administration (influenza at day 169,
exacerbation of schizophrenia at day 22, peptic ulcer at day 28,
spontaneous abortion at day 309, gastro-intestinal disturbance
due to accidental pesticide exposure at day 781, syncope and
hematoma on forehead at day 84, and nephrotic syndrome at day
14) while only one SAE (fever at day 26) was scored a possibly
related to placebo administration. A majority of participants had
SAE resolution (86%) in both groups, while ,10% were deaths
(Table 6).
Deaths. A total of 160 (1.0%) deaths occurred during the
study period: 85 vaccine and 75 placebo recipients (p=0.43).
None of the deaths was deemed related to treatment. Overall half
(54%) of the deaths in both groups were due to road traffic
accidents and trauma-associated events, followed by cardio-
vascular causes (8 cases), of which sudden unexplained death
syndrome (5 cases: 2 vaccine and 3 placebo recipients) was the
most common event.
Pregnancy outcomes. A total of 967 (30.6%) vaccine and
955 (30.1%) placebo female recipients reported a pregnancy
during the study while 139 vaccine and 116 placebo recipients
reported more than one pregnancy (Table 8).
Birth was reported for 1,843 infants, 14 of them representing 7
twin pairs. Of these, 277 births (137 vaccine and 140 placebo
recipients; 1 twin pair per treatment) occurred within 450 days of
study entry. For these infants, birth weight, gestational age and
Apgar scores were similar between the vaccine and placebo groups
(data not shown). Three congenital abnormalities (1 vaccine and 2
placebo recipients) were reported among these 277 births, the
vaccine group abnormality being a respiratory distress syndrome
with patent ductus arteriosus.
Abnormal pregnancy outcomes (APOs) were experienced in
165 out of 3165 (5.2%) vaccine and 139 out of 3169 (4.4%)
Table 3. Characteristics and overall frequency of systemic
reactions in vaccine or placebo groups.
Vaccine (n=8,096) Placebo (n=8,107)
N% n%
Headache 3,677 45.4 2,522 31.1
Fatigue 5,182 64.0 3,410 42.1
Myalgia 4,237 52.3 2,494 30.8
Arthralgia 2,177 26.9 1,246 15.4
Oral temperature $37.8uC 1,564 19.3 1,009 12.4
Nausea/Vomiting 1,080 13.3 802 9.9
Any reaction 6,251 77.2%* 4,850 59.8%
*p,0.001.
Systemic reactions following the third and fourth vaccinations could not be
attributed to either the ALVAC-HIV or AIDSVAX B/E separately as both were
administered simultaneously although in two different arms.
doi:10.1371/journal.pone.0027837.t003
Table 2. Characteristics and overall frequency of local
reactions in vaccine and placebo groups.
ALVAC – HIV AIDSVAXH B/E
Vaccine Placebo Vaccine Placebo
n=8,096 n=8,107 n=7,159 n=7,262
n% n% n% n%
Pain/Tenderness 6,852 84.6 3,727 46.0 3,543 49.5 2,991 41.2
Arm movement
limitation
5,647 69.8 2,129 26.3 2,627 36.7 1,943 26.8
Swelling 2,325 28.7 432 5.3 643 9.0 379 5.2
Erythema .0 mm 283 3.5 177 2.2 70 1.0 72 1.0
Induration .0 mm 316 3.9 108 1.3 60 0.8 53 0.7
Any local reaction 7,107 87.8* 4,210 51.9 3,908 54.6* 3,364 46.3
*p,0.001.
The proportion of participants with individual local reaction types, with the
exception of induration and erythema, was significantly higher in the vaccine
group than in the placebo group (p,0.001) for all types of reactions.
doi:10.1371/journal.pone.0027837.t002
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(p=0.13) of vaccine and placebo pregnancies, respectively.
Abnormal outcomes for first pregnancy occurred in 161 (16.6%)
and 132 (13.8%) pregnant vaccine and placebo recipients,
respectively (p=0.09). In women with their first pregnancy, the
induced abortion rate was 4.9% (94 out of 1922) while the
spontaneous abortion rate was 9.1% (175 out of 1922). The overall
rate of spontaneous and induced abortions combined was 14%
(269 out of 1922) for first pregnancies and 13.6% (297 out of 2190)
for all pregnancies.
Women agreed to avoid pregnancy from just prior to the first
injection through 3 months following final vaccination as a
precaution against adverse outcomes during the most vulnerable
stage of fetal development in the first trimester. Because vaccine
harm may differ with the period of gestation (early or late) [46],
the data were further characterized by time from last vaccination
to estimated date of conception. Among pregnancies with
estimated dates of conception within 3 months of a vaccination,
APOs occurred in 48 of 212 (22.6%) and 36 of 209 (17.2%)
vaccine and placebo recipients, respectively (p=0.18). Among
Table 4. Frequency and rates of participants with Adverse Events and Serious Adverse Events (as per definition of the U.S. Food
and Drug Administration) occurring within 30 days post each vaccination, during any 30-day post vaccination interval and any time
post first vaccination in vaccine and placebo groups.
Adverse Events Serious Adverse Events
Vaccine Placebo Total Vaccine Placebo Total
(n=8,202) (n=8,200) (n=16,402) (n=8,202) (n=8,200) (n=16,402)
D o s e n %n %n %n %n %n %
1 1,277 15.6 1,336 16.3 2,613 15.9 44 0.5 46 0.6 90 0.5
2 816 10.7 860 11.2 1,676 11.0 27 0.4 33 0.4 60 0.4
3 614 8.6 597 8.2 1,211 8.4 37 0.5 39 0.5 76 0.5
4 599 8.6 630 8.9 1,229 8.8 21 0.3 35 0.5 56 0.4
Any 30- day post vaccination interval 2,658 32.4 2,736 33.4 5,394 32.9 126 1.5 150 1.8 276 1.7
Any time post 1 5,625 68.6 5,685 69.4 11,310 69.0 1,175 14.3 1,219 14.9 2,394 14.6
Row percentages are based on the number of individuals receiving the specified dose.
doi:10.1371/journal.pone.0027837.t004
Figure 1. Percentage of individuals with local and systemic reactions by treatment and dose administered. Local reactions were
separately recorded for each of the ALVAC-HIV or placebo and AIDSVAX B/E or placebo injections since they were administered in separate arms.
Systemic reactions following the third and fourth vaccinations could not be attributed to the ALVAC-HIV or AIDSVAX B/E separately as both were
administered simultaneously, although in two different arms. Severe (dark grey), moderate (mild grey) and mild (light grey).
doi:10.1371/journal.pone.0027837.g001
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or elective induced abortions with 47 of 212 (22.2%) and 32 of 209
(15.3%) in vaccine and placebo recipients, respectively (p=0.08).
Abnormal pregnancy outcomes among pregnancies with estimated
dates of conception greater than 3 months after vaccination were
not different between study arms with 105 of 737 (14.2%) and 92
of 725 (12.7%) in vaccine and placebo recipients, respectively
(p=0.38).
Discussion
The world’s first community-based efficacy trial to test an HIV
prime-boost vaccine regimen was conducted in 16,402 healthy
Thai volunteers, providing the largest safety and reactogenicity
data set on a prime-boost regimen with ALVAC-HIV and
AIDSVAX B/E. Although the vaccine products (ALVAC-HIV
alone or in prime-boost regimens) had been previously evaluated
in different populations, the safety data from this study are similar
to previous observations in Phase I/II and III studies conducted
in Thailand and elsewhere [26,30,43,44,47]. These safety data
may be summarized as follows: most of vaccine recipients
experienced either local or systemic reactions significantly more
frequently than placebo recipients; the frequency of local
reactions such as pain and tenderness were higher than that of
systemic reactions such as headache, fatigue, arthralgia and
myalgia, although fever was rarely reported; ALVAC-HIV is
more reactogenic than AIDSVAX B/E; the frequency of the
reactions gradually declined with subsequent vaccine administra-
tions; all local and systemic reactogenicity symptoms were mild to
moderate in nature, resolving rapidly and spontaneously in the
vast majority of cases.
Routine biochemistry and hematologic laboratory values were
not assessed in RV144 based on the safety profile observed in
previous Phase I and II studies. No differences in any parameter of
renal function, hematologic abnormalities, or alterations in CD4
T-cell count were noted among recipients of ALVAC-HIV alone,
Table 6. Characteristics and frequency of adverse events and serious adverse events occurring any time after the first dose in
vaccine and placebo groups.
Adverse Events Serious Adverse Events
Vaccine Placebo Vaccine Placebo
(n=13,692) (n=13,965) (n=1,428) (n=1,484)
n% n% n % n %
Intensity Mild 6,674 48.7 6,835 48.9 3 0.2 5 0.3
Moderate 4,769 34.8 4,868 34.9 59 4.1 74 5.0
Severe/Life-threatening 2,164 15.8 2,187 15.7 1,281 89.7 1,330 89.6
Death 85 0.6 75 0.5 85 6.0 75 5.0
Relatedness Not related 13,010 95.0 13,276 95.1 1,422 99.6 1,479 99.7
Unlikely 250 1.8 285 2.0 6 0.4 4 0.3
Related 432 3.2 404 2.9 0 0 1 0.1
Serious adverse events 1,428 10.4 1,484 10.6
Change of vaccine schedule None 13,300 97.1 13,564 97.1 1,383 96.8 1,424 96.0
Delayed 358 2.6 369 2.6 22 1.5 35 2.4
Discontinued 34 0.2 32 0.2 23 1.6 25 1.7
Outcome Resolved 13,193 96.4 13,434 96.2 1,231 86.2 1,288 86.8
Resolved with sequelae 141 1.0 147 1.1 109 7.6 113 7.6
Unresolved 273 2.0 309 2.2 3 0.2 8 0.5
Death 85 0.6 75 0.5 85 6.0 75 5.1
doi:10.1371/journal.pone.0027837.t006
Table 5. Frequency of adverse (AE) and serious adverse events (SAE) by sex and age range in vaccine and placebo groups.
Vaccine Placebo
n AE (%) SAE (%) n AE (%) SAE (%)
Sex Male 5,037 65.9 13.6 5,031 67.7 13.6
Female 3,165 72.9 15.5 3,169 72.0 16.9
Age # 20 years 2,300 64.4 14.3 2,246 66.0 14.5
21–25 years 3,635 69.1 14.6 3,709 70.3 15.4
$26 years 2,267 72.0 13.9 2,245 71.1 14.4
AE rates differ by age and sex, SAE rates by sex, p,0.001.
doi:10.1371/journal.pone.0027837.t005
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control [30].
The number of cases identified as AEs fall into the usual broad
categories that were previously described in phase I/II studies.
The frequency of AEs was not significantly different between
vaccine and placebo groups. Most AEs occurred after the 30-day
post-vaccination period, 3.2% of AEs and none of SAEs being
attributed to vaccine. Female participants experienced a higher
frequency of AEs and SAEs in both vaccine and placebo groups.
The reasons for this difference are unclear. In other studies, male
participants experienced less pain than female participants
following ALVAC-HIV administration [30]. Although a fair
comparison cannot be established with Phase I/II trials of the
same vaccination regimen, their duration of follow-up being
considerably shorter, these observations are in agreement with
previous reports that there are few AEs and no SAE related to the
administration of this vaccine. In the AIDSVAX B/E phase III
trial conducted in 2546 injecting drug users (mostly male) in
Bangkok, the proportion of SAEs reported (414, 16.2%) did not
differ between vaccine and placebo groups and was similar to the
14.6% reported in this study [29].
Although ALVAC-HIV is not a vaccinia-derived vaccine, none
of the vaccinated individuals presented post vaccination symptoms
suggestive of myopericarditis events as described after smallpox
vaccination [48,49].
None of the 160 deaths reported in this trial were assessed as
related to the candidate vaccines and were mostly related to
trauma and cardiovascular causes. The number of Sudden
Unexplained Death Syndrome (SUDS) events (n=5) is less than
the expected case number (8.4) calculated from the number of
person years (32,300 male person years) and the published rate
estimate in 20–49 year old men from northeastern Thailand
(25.9/100,000 person years) [50]. In a previous AIDSVAX B/E
efficacy trial conducted in 2527 injecting drug user participants in
Bangkok, 102 deaths were reported with no difference between
vaccine and placebo recipients and none being attributed to
vaccine [29]. A similar observation was made on phase I/II trials
of ALVAC alone or ALVAC and subunit prime-boost regimens
with 7 deaths out of 1497 participants, none related to vaccination
[30].
Overall, the prime-boost regimen did not result in more
abnormal pregnancy outcomes in vaccine than in placebo female
recipients. This corroborates previous findings in phase I/II and
III trials [29,30]. In Thailand, the induced abortion ratio has been
estimated at 19.5 for 1000 live births [51] contrasting with the
4.9% reported in this study. In this study, the proportion of
induced abortions documented must be interpreted with caution,
as induced abortion is illegal in Thailand and most pregnancy
outcome data are derived from the volunteer’s report. The
spontaneous abortion rate of 9.1% is closer to the estimated rate of
6.9% formerly reported from a Thai hospital [52]. Although not
statistically significant, the higher number of abortions (spontane-
ous and induced) among vaccine recipients merits close scrutiny in
future trials of ALVAC and protein combinations.
Small clinical trials with either recombinant canarypox or
envelope subunit vaccines did not reveal safety issues in newborns
and infants from HIV-infected mothers [53–55]. Moreover, gp120
envelope subunit was shown to be safe in HIV-infected pregnant
women [56]. In several studies, ALVAC-HIV (vCP1452) has been
Table 8. Frequency of pregnancies and abnormal pregnancy outcomes (APO) in vaccine and placebo groups.
Vaccine Placebo Total P value
n% n% n%
Women recipients 3,165 50 3,169 50 6,334 100
Women with no pregnancy 2,198 69.4 2,214 69.9 4,412 69.7
Women with at least one pregnancy 967 30.6 955 30.1 1,922 30.3 0.72
Women with one pregnancy 828 26.2 839 26.5 1,667 26.3
Women with two pregnancies 132 4.2 110 3.5 242 3.8
Women with three pregnancies 7 0.2 6 0.2 13 0.2
Pregnancy occurring #3 months of last vaccination* 212 21.9 209 21.9 421 21.9
Pregnancy occurring .3 months of last vaccination* 737 76.2 725 75.9 1,462 76.1
Overall women with APO 165 5.2 139 4.4 304 4.8 0.13
Pregnant women with APO 165 17.1 139 14.6 304 15.8 0.13
APO #3 months of last vaccination 48 22.6 36 17.2 84 19.9 0.18
APO .3 months of last vaccination 105 14.2 92 12.7 197 13.5 0.38
APO in women with first pregnancy 161 16.6 132 13.8 293 15.2 0.09
*Women with known last menstrual period.
doi:10.1371/journal.pone.0027837.t008
Table 7. Frequency of common serious adverse events in
both vaccine and placebo groups according to system organ
class.
Vaccine Placebo
nn
Injury, poisoning and procedural complication 529 549
Infection and infestation 363 370
Pregnancy and associated conditions 187 194
Gastro-intestinal disorders 103 100
Psychiatric disorders 37 42
doi:10.1371/journal.pone.0027837.t007
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jects [57–59]. ALVAC recombinants have been administered to
humans and animals by parenteral and oral routes without signs of
replication, systemic dissemination or severe reaction. In principle,
it should be impossible for canarypox recombinants to disseminate
in the environment, as the recombinants would not be synthesized
in mammalian cells as complete virus. ALVAC is an attenuated
canarypox virus and is non-pathogenic in its host species, other
birds, mammals and humans. It may be infectious for birds,
though there are already five canarypox-based veterinary vaccines
[60].
The results of the ALVAC-HIV and AIDSVAX B/E prime-
boost regimen confirm that the regimen is safe and well tolerated
among a large population of healthy HIV-uninfected adults in
Thailand. Although occurrence of local and systemic reactions was
reported among the vaccinated participants, very few adverse
events were related to the vaccine products. No death was
attributed to the vaccination regimen. Altogether, these findings
indicate that ALVAC-HIV and AIDSVAX B/E are safe and well
tolerated and may be suitable for further study and large-scale
public use, should efficacy be judged adequate to have a public
health impact.
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